Vizuri Health Sciences LLC’s PainBloc24® Partners with the Arthritis Foundation, Inc. to Help Afflicted Millions Get a Grip on Arthritis

Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the formation of a partnership between Vizuri’s PainBloc24® product and the Arthritis Foundation, and the Foundation’s “Let’s Get a Grip on Arthritis” campaign.

 
 
 

FAIRFAX, Va.--(BUSINESS WIRE)-- Vizuri Health Sciences LLC, a pharmaceutical and over-the-counter (OTC) product development company, today announced the formation of a partnership between Vizuri’s PainBloc24® product and the Arthritis Foundation, and the Foundation’s “Let’s Get a Grip on Arthritis” campaign. PainBloc24® will be recognized as a Supporting Partner of the campaign during Arthritis Awareness Month in May and throughout the year.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181016005043/en/

Vizuri Health Sciences Aligns Its Non-opioid Pain Management Assets with the Arthritis Foundation's  ...

Vizuri Health Sciences Aligns Its Non-opioid Pain Management Assets with the Arthritis Foundation's Goals to Raise Awareness and Find a Cure (Photo: Business Wire)

William Moore, Ph.D., Vizuri’s President and Chief Executive Officer explained, “Vizuri Health Sciences shares the Arthritis Foundation’s vision of a pain-free future for millions of Americans living with arthritis as well as those who have yet to be diagnosed. This partnership aligns Vizuri’s mission to provide those with arthritis safe, effective, self-administered, non-addictive pain relief products with the Arthritis Foundation’s mission to provide these individuals a personalized plan for living a full life while striving for a cure.”

“The Arthritis Foundation is pleased to have Vizuri’s PainBloc24 as a part of the ‘Let’s Get a Grip on Arthritis campaign’,” said Ann McNamara, the Foundation’s Senior Vice President. “Having options for the debilitating pain arthritis causes can make a big difference in the quality of people’s lives.”

Let’s get a grip on arthritis.
More than 54 million Americans have been diagnosed with arthritis, which the Arthritis Foundation believes is a conservative number because many people don’t seek treatment until their symptoms become severe. An estimated one in three people ages 18-65 currently lives with the disease, and more than half of those reported that arthritis limits their activity, making everyday tasks difficult and painful. Perhaps even worse is that arthritis often forces people to give up the things they love to do and are passionate about, like a hobby, sports or favorite pastime.

The Arthritis Foundation, with the help of Vizuri, is asking all Americans to support and rally around “Let’s Get a Grip on Arthritis.” Visit www.arthritis.org/LetsGripArthritis to donate and learn more about the campaign. Use the hashtag #LetsGripArthritis to join the social media movement.

About Vizuri Health Sciences LLC (www.vizuriusa.com)
Privately-owned Vizuri develops and markets new innovative pharmaceutical and OTC products. The products comprise proprietary formulations that use patented technologies to enhance the efficacy and safety of natural and pharmaceutical ingredients that have proven health benefits.

The company recently introduced PainBloc24®, the first OTC topical pain reliever that can help provide 24-hour arthritis pain relief with as little as one application every day. PainBloc24® utilizes a patented NeuroMax® formula, that consists of several safe, non-active ingredients that enhance the tolerability and effectiveness of the naturally-occurring, FDA-recognized, topical analgesic, capsaicin. PainBloc24® contains the highest concentration of capsaicin allowed by FDA without a prescription. It was demonstrated in an osteoarthritis knee pain clinical study that PainBloc24® can help provide 24-hour pain relief when applied one to two times every day.

PainBloc24® is currently available at select drug and grocery retail stores including Walgreens, CVS, Rite Aid, Publix, Kroger, Giant Eagle, and Meijer among others. Find a retailer near you.

The company is also developing prescription-strength, capsaicin products CGS-200-1 (1% capsaicin) and CGS-200-5 (5% capsaicin) that are currently being evaluated in a Phase 2 clinical study for the relief of osteoarthritic knee pain. The CGS-200 formulations contain up to twenty times greater concentrations of capsaicin than does PainBloc24®. CGS-200, like PainBloc24®, utilizes the patented, innovative NeuroMax® formula. Vizuri believes that PainBloc24® and the CGS-200 products represent promise as safer, non-addictive alternatives to opioids, steroids, and NSAIDs for the management of pain in joints in addition to the knee, thereby positioning them more broadly as potential treatments for musculoskeletal pain. Like PainBloc24®, the CGS-200 products, can be conveniently self-administered without a need for prior treatment of the affected area with cooling or a with a topical or injected analgesic. Vizuri wholly owns its patented PainBloc24® and CGS-200 products.

About the Arthritis Foundation (www.arthritis.org)
The Arthritis Foundation is the arthritis community’s Champion of Yes. The Foundation’s goal is to chart a winning course, guiding families in developing personalized plans for living a full life while striving for a cure. The Arthritis Foundation helps people living with arthritis through its strategic pillars of scientific discovery, help and support, advocacy and access, and juvenile arthritis. The Foundation also publishes Arthritis Today, the award-winning magazine that reaches 4.2 million readers.

 

Contacts

Vizuri Health Sciences LLC
William Moore, 443-961-8231
CEO
wmoore@vizuriusa.com

 
 

Source: Vizuri Health Sciences LLC

Smart Multimedia Gallery

Vizuri Health Sciences Aligns Its Non-opioid Pain Management Assets with the Arthritis Foundation's Goals to Raise Awareness and Find a Cure (Photo: Business Wire)

View this news release and multimedia online at:
http://www.businesswire.com/news/home/20181016005043/en

MORE ON THIS TOPIC